Volume | 826,601 |
|
|||||
News | - | ||||||
Day High | 76.89 | Low High |
|||||
Day Low | 73.6884 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Intra Cellular Therapies Inc | ITCI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
75.06 | 73.6884 | 76.89 | 74.01 | 74.54 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,149 | 826,601 | $ 75.17 | $ 62,136,178 | - | 45.50 - 84.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:47:42 | 1 | $ 75.88 | USD |
Intra Cellular Therapies (ITCI) Options Flow Summary
Intra Cellular Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.16B | 96.81M | - | 464.37M | -139.67M | -1.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Intra Cellular Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITCI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 75.29 | 84.89 | 70.93 | 76.04 | 3,813,811 | -1.28 | -1.70% |
1 Month | 68.88 | 84.89 | 64.155 | 73.69 | 1,392,501 | 5.13 | 7.45% |
3 Months | 69.66 | 84.89 | 62.78 | 71.44 | 980,468 | 4.35 | 6.24% |
6 Months | 49.95 | 84.89 | 45.50 | 65.81 | 958,103 | 24.06 | 48.17% |
1 Year | 62.34 | 84.89 | 45.50 | 63.06 | 829,532 | 11.67 | 18.72% |
3 Years | 30.50 | 84.89 | 28.40 | 53.88 | 769,044 | 43.51 | 142.66% |
5 Years | 12.64 | 84.89 | 6.75 | 38.35 | 942,075 | 61.37 | 485.52% |
Intra Cellular Therapies Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |